TAVR Replaces the Aortic Valve Without Open Surgery. The PARTNER Trial Showed Equivalent Outcomes to Surgical Replacement.

The Scene

The following scene is drawn from the composite of patients I have cared for in clinic and on the hospital floor. All identifying details are changed.

Margaret is 82 years old. She grew up in Decatur, Illinois, raised four children, and walked two miles every morning until 18 months ago. Then the walks got shorter. Then they stopped. She blamed it on her knee. Her cardiologist blamed it on her heart.

Her echocardiogram showed a severely stenotic aortic valve: mean gradient 52 mmHg, valve area 0.6 cm2. Her surgeon reviewed the films. Margaret’s STS operative risk score for open aortic valve replacement was 8.2%: high surgical risk. Her cardiologist mentioned TAVR.

Margaret had no frame of reference for TAVR. She knew what “heart surgery” meant, at least in the conceptual sense of opening the chest, stopping the heart, putting the patient on bypass. She did not know that there was a way to replace a heart valve through a catheter threaded up through the femoral artery from the groin.

In 2003, a team led by Alain Cribier performed the first human TAVR in Rouen, France, in a patient with severe AS who could not tolerate surgery 5 / Solid . The procedure that was experimental in 2003 now accounts for more than half of all aortic valve replacements performed in the United States.

What It Is

Transcatheter aortic valve replacement is a minimally invasive procedure in which a new bioprosthetic aortic valve, mounted on a collapsible metallic frame, is delivered via catheter to the aortic annulus and deployed in place of the native diseased valve. The native valve leaflets are pushed aside (not removed) by the expanding new valve frame. Blood flow is immediately restored through the new valve.

TAVR treats severe aortic stenosis (AS), the most common valvular heart disease in adults older than 65 in the Western world, affecting approximately 2 to 5% of adults older than 65 5 / Solid 00075-6). Untreated severe symptomatic aortic stenosis carries an annual mortality of 25 to 50% depending on the presenting symptom: angina (average survival 5 years), syncope (3 years), heart failure (2 years) 5 / Solid .

The Two Dominant Platforms

Balloon-expandable (SAPIEN family, Edwards Lifesciences): SAPIEN XT, SAPIEN 3, SAPIEN 3 Ultra. The valve frame is made of cobalt-chromium; the leaflets are bovine pericardium. Delivery is on a balloon catheter; the balloon is inflated once to expand the frame to its predetermined size. The SAPIEN 3 Ultra Resilia represents the current generation.

Self-expanding (Evolut family, Medtronic): Evolut R, Evolut PRO, Evolut FX. The valve frame is nitinol, which expands spontaneously when released from the delivery catheter and can be partially recaptured during deployment for repositioning. The leaflets are porcine pericardium.

The choice between platforms is determined by anatomical characteristics (annulus size, degree of calcification, coronary anatomy), operator experience, and institutional preference. Outcomes are broadly comparable across platforms in most patient subgroups, though subtle hemodynamic and anatomical differences exist.

The Mechanism

Why the Aortic Valve Fails

Calcific aortic stenosis is not simply aging. It is an active inflammatory and calcific process involving the same risk factors as atherosclerosis: LDL-C, Lp(a), hypertension, diabetes, and smoking. Increased Lp(a) specifically is the strongest genetic risk factor for calcific aortic stenosis 5 / Solid . Lipid deposition in the valve leaflets triggers macrophage infiltration, osteoblast-like change of valve interstitial cells, and calcification of the leaflet bodies. The result is progressive leaflet thickening, restricted opening (reduced valve area), and increased transvalvular gradient.

The normal aortic valve area is 3.0 to 4.0 cm2. Severe AS is defined as valve area below 1.0 cm2 (or indexed area below 0.6 cm2/m2) with mean gradient above 40 mmHg 5 / Solid . The hemodynamic consequence is increased left ventricular afterload: the LV must generate progressively higher pressures to maintain forward flow. Over years, the LV undergoes concentric hypertrophy, diastolic dysfunction, and ultimately systolic dysfunction if the stenosis is not relieved.

How TAVR Deploys

The most common access route is transfemoral: the femoral artery at the groin is punctured (or surgically exposed in patients with small or diseased femoral arteries), and a large-bore delivery sheath (14 to 18 French, approximately 4.7 to 6 mm) is advanced into the descending aorta. A balloon valvuloplasty is performed to crack the calcified native leaflets. The compressed new valve, mounted on its delivery system, is advanced across the aortic arch and positioned within the native aortic annulus under fluoroscopic and echocardiographic guidance (transesophageal echo, TEE, is standard). For balloon-expandable valves, rapid ventricular pacing at 180 to 200 bpm briefly reduces cardiac output during valve deployment to prevent the balloon from migrating. For self-expanding valves, deployment is gradual and can be partially reversed.

Alternative access routes include transapical (through the apex of the LV via a small left thoracotomy), transcaval (through the inferior vena cava), transaortic (via a mini-sternotomy), and transaxillary (via the axillary artery). These alternative routes are used when femoral access is prohibitive due to vessel size, calcification, or tortuosity.

Paravalvular Leak

Because the TAVR valve is not sewn to the annulus but rather radially expanded within it, mild paravalvular leak (blood flowing around the outside of the valve frame, between the frame and the native annulus) is common. Moderate or severe paravalvular leak is associated with worse outcomes, including excess mortality 5 / Solid . Contemporary valve designs (SAPIEN 3 outer skirt, Evolut PRO pericardial wrap) have substantially reduced paravalvular leak rates relative to early designs.

Conduction Disturbances

The aortic valve annulus is anatomically adjacent to the His bundle and left bundle branch. Valve deployment can compress or injure the conduction system, producing left bundle branch block (LBBB) or complete heart block requiring permanent pacemaker implantation. New permanent pacemaker rates: 15 to 25% with self-expanding Evolut valves versus 5 to 8% with balloon-expandable SAPIEN valves, attributable to differences in valve depth and radial force 5 / Solid .

How It Is Used

Indication by Risk Tier

TAVR’s FDA-approved indication expanded progressively as trial evidence accumulated across risk tiers:

• Inoperable (PARTNER B, 2010): TAVR vs. medical management; first FDA approval 2011.
• High surgical risk (PARTNER A, 2011): TAVR vs. surgical AVR (SAVR); Class I indication.
• Intermediate surgical risk (PARTNER 2, SURTAVI, 2016-2017): TAVR non-inferior to SAVR; Class IIa, upgraded to Class I in 2021 guidelines.
• Low surgical risk (PARTNER 3, EVOLUT Low-Risk, 2019): TAVR non-inferior to SAVR; Class I in current guidelines for appropriately selected anatomy.

Current ACC/AHA Valvular Heart Disease Guidelines (2021) give TAVR a Class I recommendation for symptomatic severe AS when TAVR is preferred over SAVR by the Structural Heart Disease Team based on patient anatomy, age, and preference 5 / Solid .

Anatomical Requirements and Limitations

Not every patient with severe AS is an appropriate TAVR candidate. Anatomical requirements include:

• Minimum femoral artery diameter of 5.0 to 6.0 mm for transfemoral access with current delivery systems
• Aortic annulus diameter within the range of available valve sizes (18 to 29 mm for SAPIEN 3; Evolut sizes available for annuli up to 30 mm)
• Coronary ostia height adequate to avoid coronary obstruction during deployment (height above 10 mm required for most native valve implants; coronary protection procedures are available when heights are borderline)
• Acceptable valve morphology: bicuspid aortic valve TAVR carries higher risk of paravalvular leak, malpositioning, and annular rupture 4 / Promising

The Structural Heart Disease Team Model

TAVR decision-making requires a multidisciplinary Structural Heart Disease Team including interventional cardiology (structural), cardiac surgery, cardiac imaging, and cardiac anesthesia. This team model is a Class I recommendation in ACC/AHA guidelines. Centers performing TAVR must meet minimum institutional volume requirements (50 procedures annually) and operator experience requirements to maintain ACC/AHA center certification 5 / Solid .

Geographic Access

TAVR programs are concentrated at tertiary and quaternary cardiac centers. In Illinois, TAVR is performed at Northwestern Medicine Bluhm Cardiovascular Institute in Chicago, University of Illinois Health in Chicago, OSF Saint Francis Medical Center in Peoria, and Advocate Aurora Health System in the Chicago suburbs. Patients from central Illinois, including those served by Carle Foundation Hospital, are typically referred to one of these programs. Medicare covers TAVR at approved TAVR centers nationwide; 2022 changes to national coverage determination removed many earlier volume restrictions.

The Evidence

PARTNER 1B: TAVR vs. Medical Management in Inoperable Patients

PARTNER 1B (Leon MB, et al. N Engl J Med. 2010; doi:10.1056/NEJMoa1008232) enrolled 358 patients with inoperable severe AS randomized to TAVR (SAPIEN, transfemoral or transapical) versus standard medical management including balloon valvuloplasty. At 1 year, all-cause mortality was 30.7% in the TAVR group versus 50.7% in the control group (HR 0.55, 95% CI 0.40 to 0.74; p < 0.001) 5 / Solid . Repeat hospitalization: 22.3% TAVR vs. 44.1% standard therapy (p < 0.001). What PARTNER 1B did not show: the trial used first-generation SAPIEN valves with higher paravalvular leak and vascular complication rates than contemporary devices; outcomes with modern valves should be better.

PARTNER 1A: TAVR vs. SAVR in High Surgical Risk

PARTNER 1A (Smith CR, et al. N Engl J Med. 2011; doi:10.1056/NEJMoa1103510) enrolled 699 high surgical risk patients (STS score above 10%) randomized to TAVR versus SAVR. At 1 year, all-cause mortality: 24.2% TAVR vs. 26.8% SAVR (p = 0.001 for non-inferiority) 5 / Solid . Stroke at 30 days was higher in the TAVR arm (3.8% vs. 2.1%; p = 0.20), and vascular complications were higher. Major bleeding and new AF were higher with SAVR.

PARTNER 2: TAVR vs. SAVR in Intermediate Risk

PARTNER 2 (Leon MB, et al. N Engl J Med. 2016; doi:10.1056/NEJMoa1514616) enrolled 2,032 intermediate-risk patients (STS 4 to 8%) randomized to SAPIEN XT vs. SAVR. At 2 years, death or disabling stroke: 19.3% TAVR vs. 21.1% SAVR (HR 0.89, 95% CI 0.73 to 1.09; p < 0.001 for non-inferiority) 5 / Solid . In the transfemoral-access subgroup, TAVR was superior to SAVR (HR 0.79, 95% CI 0.62 to 1.00; p = 0.05). New AF higher with SAVR; paravalvular leak higher with TAVR.

PARTNER 3: TAVR vs. SAVR in Low Surgical Risk

PARTNER 3 (Mack MJ, et al. N Engl J Med. 2019; doi:10.1056/NEJMoa1814052) enrolled 1,000 low-risk patients (STS below 4%) randomized to SAPIEN 3 vs. SAVR. At 1 year, death, stroke, or rehospitalization: 8.5% TAVR vs. 15.1% SAVR (HR 0.54, 95% CI 0.37 to 0.79; p < 0.001 for superiority) 5 / Solid . This represented the first superiority result for TAVR vs. SAVR in any risk tier. Major drivers were lower AF (5.0% vs. 39.5%) and lower rehospitalization (3.4% vs. 6.5%). What PARTNER 3 did not show: follow-up was only 1 year; valve durability and the long-term hemodynamic advantage of surgical bioprostheses in younger patients are unresolved.

EVOLUT Low-Risk: Self-Expanding Valve in Low Surgical Risk

EVOLUT Low-Risk (Popma JJ, et al. N Engl J Med. 2019; doi:10.1056/NEJMoa1816885) enrolled 1,468 low-risk patients randomized to Evolut R/PRO self-expanding valve vs. SAVR. At 24 months, death or disabling stroke: 5.3% TAVR vs. 6.7% SAVR (p < 0.001 for non-inferiority) 5 / Solid . Pacemaker implantation was 17.4% in the TAVR arm vs. 6.1% in the SAVR arm.

Valve Durability at 5 and 10 Years

The durability question is the central unresolved issue for TAVR in younger patients. SAVR bioprosthetic valves have 15- to 20-year durability data. TAVR has 5- to 10-year data.

The PARTNER 2 5-year outcomes (Thourani VH, et al. JACC Cardiovasc Interv. 2019; doi:10.1016/j.jcin.2019.07.001) showed no significant difference in all-cause mortality, and structural valve deterioration rates were similar to SAVR at 5 years 4 / Promising . The 10-year data from PARTNER 1 high-risk cohort showed TAVR durability comparable to SAVR at 10 years in high-risk patients (Mack MJ, et al. N Engl J Med. 2022; doi:10.1056/NEJMoa2200803) 4 / Promising . Data beyond 10 years remain limited. For a 70-year-old patient with expected 15-year survival, the durability question is less pressing than for a 55-year-old.

Stroke Risk

Early TAVR (within 30 days) stroke rates are 2 to 5% in most trials, largely attributable to calcific embolism during valve deployment. Cerebral embolic protection devices (Claret Sentinel, Keystone Heart TriGuard) capture emboli before they reach the cerebral circulation. The PROTECTED TAVR trial (Kapadia SR, et al. N Engl J Med. 2022; doi:10.1056/NEJMoa2204961) enrolled 3,000 patients randomized to TAVR with vs. without Sentinel cerebral embolic protection. The primary outcome of stroke within 72 hours did not differ significantly (2.3% vs. 2.9%; p = 0.30), though disabling stroke was significantly lower with protection (0.5% vs. 1.1%; p = 0.02) 5 / Solid .

The Patient Experience

Margaret’s TAVR procedure at a Chicago tertiary center took 90 minutes. She was under general anesthesia with TEE guidance. She woke up without a chest tube, without a sternal incision, with a small dressing at her right groin.

She went home on post-procedure day 2. Her echocardiogram before discharge showed a mean gradient of 8 mmHg (down from 52) and no more than trace paravalvular leak.

Six weeks later, she walked a mile without stopping.

What Your Cardiologist Will Not Have Time to Explain

• The valve is not magnetic. TAVR valves contain metallic frames (nitinol or cobalt-chromium) but are not ferromagnetic. They are safe for MRI immediately after implantation. This is different from some older surgical prostheses.

• You will carry a valve card. The implanting center provides a wallet card listing the valve type, size, and serial number. Keep this. Show it to every cardiologist, dentist, and surgeon you see for the rest of your life. Antibiotic prophylaxis before dental procedures is required for TAVR valves under current AHA guidelines 5 / Solid .

• Pacemaker risk is real and should be discussed specifically. If you receive a self-expanding Evolut valve, your risk of needing a permanent pacemaker within 30 days is approximately 17 to 25%. If you receive a SAPIEN 3, it is approximately 5 to 8%. If you have a pre-existing right bundle branch block, your pacemaker risk is substantially higher regardless of valve type. Ask your team what your individual risk is before the procedure.

• TAVR valves will eventually fail. The word “replacement” implies permanence, but bioprosthetic valve leaflets calcify and degrade over time. In most high-risk patients, the valve will outlast the patient. In younger patients (below 65), the valve may require reintervention within 15 to 20 years. “Valve-in-valve” TAVR (implanting a new transcatheter valve within a failed TAVR) is feasible in most cases; the anatomical and procedural requirements for this possibility should be discussed at the time of the initial TAVR.

• Post-TAVR anticoagulation is not standardized. Most centers use dual antiplatelet therapy (aspirin plus clopidogrel) for 3 to 6 months post-TAVR, then aspirin alone. For patients with AF or other anticoagulation indications, direct oral anticoagulants or warfarin are used. The GALILEO trial (Nijenhuis VJ, et al. N Engl J Med. 2019; doi:10.1056/NEJMoa1907447) showed that rivaroxaban-based therapy was associated with higher all-cause mortality and thromboembolic complications versus antiplatelet therapy in TAVR patients without AF 5 / Solid , making routine anticoagulation the incorrect approach in patients without a separate anticoagulation indication.

Sex Differences in TAVR

Women have smaller aortic annuli than men, which historically led to sizing challenges with early-generation large-diameter delivery systems. With contemporary low-profile systems, technical success rates are comparable by sex. Women presenting with severe AS have worse baseline functional status on average and are more likely to have low-gradient AS despite severe obstruction (paradoxical low-flow, low-gradient AS), which requires careful hemodynamic assessment 5 / Solid . Post-TAVR outcomes for women are similar to or slightly better than for men when procedural complications are controlled for 4 / Promising .

Decisions and Trade-Offs

TAVR vs. SAVR: The Age-Based Framework

The 2021 ACC/AHA Valvular Heart Disease Guidelines offer this practical framework:

• Age above 80 or life expectancy below 10 years: TAVR preferred (Class I).
• Age 65 to 80: Shared decision-making based on anatomy, durability concerns, and patient preference; either TAVR or SAVR reasonable (Class I for both in appropriate anatomy).
• Age below 65: SAVR generally preferred due to durability concerns; TAVR reasonable if anatomy is favorable and patient preference strongly favors the less invasive approach (Class IIa).

The Asymptomatic AS Dilemma

Current guidelines require symptoms (angina, syncope, or heart failure) before recommending TAVR or SAVR for most patients with severe AS. The natural history data show that symptom onset predicts rapid mortality decline, which has led some centers to pursue early intervention before symptoms develop.

The RECOVERY trial (Kang DH, et al. N Engl J Med. 2020; doi:10.1056/NEJMoa1912428) enrolled 145 patients with truly asymptomatic severe AS (AVA below 0.75 cm2, peak velocity above 4.5 m/s) randomized to early surgery versus watchful waiting. The early surgery group had dramatically lower operative mortality and composite adverse events at 4 years (HR 0.27, 95% CI 0.13 to 0.53) 5 / Solid . This trial supports considering earlier intervention in asymptomatic severe AS with very high-risk features; the ongoing AVATAR and EVoLVeD trials are examining this question for TAVR specifically 4 / Promising .

What Untreated Severe Symptomatic AS Means

For a patient with severe symptomatic AS who declines intervention, the survival data are grim. Median survival after syncope is approximately 3 years; after angina, 5 years; after heart failure symptoms, 1 to 2 years 5 / Solid . These are median estimates from 1960s-era data, and best available medical management may modestly extend survival; however, there is no pharmacological therapy that reliably halts AS progression or reduces its mortality.

The Three Questions Every Patient Should Ask

1. “Am I eligible for transfemoral TAVR, or will an alternative access approach be needed?” Transfemoral TAVR has the lowest complication rate; alternative access routes carry higher procedural risk.

2. “What are the pacemaker implantation rates at your center with the specific valve type you plan to use for me?” This should be a precise, center-specific answer, not a generic trial statistic.

3. “What is the plan for valve failure in 10 to 15 years? Is my anatomy suitable for valve-in-valve TAVR?” For younger patients, planning for the future procedure is part of planning the current one.

Clinical Synthesis

Aortic stenosis is the cardiovascular disease most strongly associated with Lp(a). Margaret’s Lp(a) was never measured. Lp(a) above 125 nmol/L (roughly 50 mg/dL) is associated with a threefold increased risk of calcific AS, independent of LDL-C 5 / Solid . There are no approved Lp(a)-lowering therapies as of 2026, though three trials are in late-stage development (OCEAN(a)-Outcomes for olpasiran, Lp(a)HORIZON for pelacarsen, APOLLO for muvalaplin). But measuring Lp(a) in Margaret’s children matters now. It changes their risk assessment.

The core clinical thesis on TAVR is not about TAVR itself. TAVR is a remarkable procedure that has changed aortic stenosis from a death sentence for the surgically ineligible into a manageable condition. The thesis question is: which patients should have known their Lp(a) at age 50, received earlier statin therapy and aggressive Lp(a) surveillance, and had their calcific AS diagnosed before the valve reached critical severity?

If you have been told you have severe aortic stenosis: a structured cardiovascular assessment reviews whether your Structural Heart Disease Team has been engaged, whether your coronary anatomy has been fully characterized (concurrent significant CAD affects the TAVR-vs-SAVR decision), and what the anticoagulation plan is post-procedure.

If you have moderate aortic stenosis under surveillance: The Signal Check addresses the interval imaging schedule, the symptom threshold for re-referral, and the risk factor management (particularly lipid control) that may slow progression.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.